2024-21086. Medical Devices; Immunology and Microbiology Devices; Classification of the Quantitative Viral Nucleic Acid Test for Transplant Patient Management  

  • Table 1—Quantitative Viral Nucleic Acid Test for Transplant Patient Management Risks and Mitigation Measures

    Identified risks to health Mitigation measures
    Risk of false results Certain warnings, limitations, results interpretation information, and explanation of procedures in labeling; and Certain device descriptions and specifications, analytical studies, clinical studies, and risk analysis in design verification and validation.
    Failure to correctly interpret test results Certain warnings, limitations, results interpretation information, and explanation of procedures in labeling.
    Failure to correctly operate the device Certain warnings, limitations, results interpretation information, and explanation of procedures in labeling.

Document Information

Effective Date:
9/17/2024
Published:
09/17/2024
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final amendment; final order.
Document Number:
2024-21086
Dates:
This order is effective September 17, 2024. The classification was applicable on July 30, 2020.
Pages:
75953-75955 (3 pages)
Docket Numbers:
Docket No. FDA-2024-N-4084
Topics:
Biologics, Laboratories, Medical devices
PDF File:
2024-21086.pdf
CFR: (1)
21 CFR 866